Homozygous Familial Hypercholesterolemia Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Arrowhead Pharmaceutical, Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Novartis, Ultragen

DelveInsight's "Homozygous Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Homozygous Familial Hypercholesterolemia, historical and forecasted epidemiology as well as the Homozygous Familial Hypercholesterolemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Homozygous Familial Hypercholesterolemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Homozygous Familial Hypercholesterolemia Market Forecast

Some of the key facts of the Homozygous Familial Hypercholesterolemia Market Report: https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• The Homozygous Familial Hypercholesterolemia market size was valued approximately USD 108 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• As of 2022, the market size for homozygous familial hypercholesterolemia was most significant in the US compared to the other countries in the 7MM, reaching around USD 83.37 million. Projections indicate an anticipated rise in this market size by the year 2032.
• Around 2,845 diagnosed prevalent cases of HoFH were recorded in the 7MM. These numbers are projected to experience a slight increase by 2032, with a Compound Annual Growth Rate (CAGR) of 0.3% anticipated during the study period from 2019 to 2032.
• Within the 7MM, both the EU4 and the UK together represented around 38% of the entire diagnosed prevalent cases of HoFH. This proportion is projected to expand further over the study duration.
• Of the approved products, EVKEEZA (evinacumab) from Regeneron/Ultragenyx, the pioneering ANGPTL3 inhibitor authorized for managing extremely elevated LDL-C levels in children as young as 5 years old, received approval in 2021. Its revenue in the US amounted to USD 47 million in 2022, constituting almost 56% of the entire homozygous familial hypercholesterolemia market in the US.
• Key Homozygous Familial Hypercholesterolemia Companies: Arrowhead Pharmaceutical, Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Novartis, Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, Sanofi, Cerenis Therapeutics, Aegerion Pharmaceuticals, The Medicines Company, Akeso, Aegerion Pharmaceuticals, and others
• Key Homozygous Familial Hypercholesterolemia Therapies: ARO-ANG3, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), Lomitapide, Inclisiran, Evinacumab, ARO-ANG 3 Injection, Alirocumab, CER-001, lomitapide, ALN-PCSSC, AK102, AEGR-733, and others
• The Homozygous Familial Hypercholesterolemia epidemiology based on mutation-specific cases analyzed that a mutation in the LDLR gene accounted for the highest diagnosed prevalent cases in the US
• The Homozygous Familial Hypercholesterolemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Homozygous Familial Hypercholesterolemia pipeline products will significantly revolutionize the Homozygous Familial Hypercholesterolemia market dynamics.

Homozygous Familial Hypercholesterolemia Overview
HoFH, standing for homozygous familial hypercholesterolemia, is a rare and severe genetic disorder impacting cholesterol metabolism. It arises from genetic mutations occurring in both copies of the LDLR gene (low-density lipoprotein receptor), or in other genes associated with cholesterol metabolism, like APOB or PCSK9 genes. The LDLR gene is responsible for producing a receptor essential in eliminating low-density lipoprotein (LDL) cholesterol from the bloodstream.

Get a Free sample for the Homozygous Familial Hypercholesterolemia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Homozygous Familial Hypercholesterolemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Homozygous Familial Hypercholesterolemia Epidemiology Segmentation:
The Homozygous Familial Hypercholesterolemia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Homozygous Familial Hypercholesterolemia
• Prevalent Cases of Homozygous Familial Hypercholesterolemia by severity
• Gender-specific Prevalence of Homozygous Familial Hypercholesterolemia
• Diagnosed Cases of Episodic and Chronic Homozygous Familial Hypercholesterolemia

Download the report to understand which factors are driving Homozygous Familial Hypercholesterolemia epidemiology trends @ Homozygous Familial Hypercholesterolemia Epidemiology Forecast
https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Homozygous Familial Hypercholesterolemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Homozygous Familial Hypercholesterolemia market or expected to get launched during the study period. The analysis covers Homozygous Familial Hypercholesterolemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Homozygous Familial Hypercholesterolemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Homozygous Familial Hypercholesterolemia Therapies and Key Companies
• ARO-ANG3: Arrowhead Pharmaceutical
• LEQVIO (inclisiran/KJX839: Novartis/ Alnylam Pharmaceutical
• Lerodalcibep (LIB003): LIB Therapeutics
• Lomitapide: Amryt Pharma
• Inclisiran: Novartis
• Evinacumab: Ultragenyx Pharmaceutical
• ARO-ANG 3 Injection: Arrowhead Pharmaceuticals
• Alirocumab: Sanofi
• CER-001: Cerenis Therapeutics
• lomitapide: Aegerion Pharmaceuticals
• ALN-PCSSC: The Medicines Company
• AK102: Akeso
• AEGR-733: Aegerion Pharmaceuticals

Discover more about therapies set to grab major Homozygous Familial Hypercholesterolemia market share @ Homozygous Familial Hypercholesterolemia Treatment Landscape
https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Homozygous Familial Hypercholesterolemia Market Drivers
• The clarity in disease understanding and pathogenesis have driven the development of novel pharmacological options like PCSK9inhibitors, ANGPTL3 inhibitor, and MTP inhibitor.
• Advances in research have led to the discovery of novel molecules like siRNA and recombinant fusion protein that may offer novel options to lower LDL significantly.

Homozygous Familial Hypercholesterolemia Market Barriers
• Preclinical studies have yielded gene therapy and CRISPR-based gene editing approaches; conducting further research and clinical trials may offer curative therapy.
• Advancements in healthcare technologies and digital health solutions can potentially enhance the early detection and personalized management of HoFH.

Scope of the Homozygous Familial Hypercholesterolemia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Homozygous Familial Hypercholesterolemia Companies: Arrowhead Pharmaceutical, Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Novartis, Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, Sanofi, Cerenis Therapeutics, Aegerion Pharmaceuticals, The Medicines Company, Akeso, Aegerion Pharmaceuticals, and others
• Key Homozygous Familial Hypercholesterolemia Therapies: ARO-ANG3, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), Lomitapide, Inclisiran, Evinacumab, ARO-ANG 3 Injection, Alirocumab, CER-001, lomitapide, ALN-PCSSC, AK102, AEGR-733, and others
• Homozygous Familial Hypercholesterolemia Therapeutic Assessment: Homozygous Familial Hypercholesterolemia current marketed and Homozygous Familial Hypercholesterolemia emerging therapies
• Homozygous Familial Hypercholesterolemia Market Dynamics: Homozygous Familial Hypercholesterolemia market drivers and Homozygous Familial Hypercholesterolemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Homozygous Familial Hypercholesterolemia Unmet Needs, KOL's views, Analyst's views, Homozygous Familial Hypercholesterolemia Market Access and Reimbursement

To know more about Homozygous Familial Hypercholesterolemia companies working in the treatment market, visit @ Homozygous Familial Hypercholesterolemia Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Homozygous Familial Hypercholesterolemia Market Report Introduction
2. Executive Summary for Homozygous Familial Hypercholesterolemia
3. SWOT analysis of Homozygous Familial Hypercholesterolemia
4. Homozygous Familial Hypercholesterolemia Patient Share (%) Overview at a Glance
5. Homozygous Familial Hypercholesterolemia Market Overview at a Glance
6. Homozygous Familial Hypercholesterolemia Disease Background and Overview
7. Homozygous Familial Hypercholesterolemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Homozygous Familial Hypercholesterolemia
9. Homozygous Familial Hypercholesterolemia Current Treatment and Medical Practices
10. Homozygous Familial Hypercholesterolemia Unmet Needs
11. Homozygous Familial Hypercholesterolemia Emerging Therapies
12. Homozygous Familial Hypercholesterolemia Market Outlook
13. Country-Wise Homozygous Familial Hypercholesterolemia Market Analysis (2019-2032)
14. Homozygous Familial Hypercholesterolemia Market Access and Reimbursement of Therapies
15. Homozygous Familial Hypercholesterolemia Market Drivers
16. Homozygous Familial Hypercholesterolemia Market Barriers
17. Homozygous Familial Hypercholesterolemia Appendix
18. Homozygous Familial Hypercholesterolemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Homozygous Familial Hypercholesterolemia Pipeline https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Homozygous Familial Hypercholesterolemia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Homozygous Familial Hypercholesterolemia market. A detailed picture of the Homozygous Familial Hypercholesterolemia pipeline landscape is provided, which includes the disease overview and Homozygous Familial Hypercholesterolemia treatment guidelines.
Homozygous Familial Hypercholesterolemia Epidemiology https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Homozygous Familial Hypercholesterolemia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Homozygous Familial Hypercholesterolemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Lung Transplant Rejection Market https://www.delveinsight.com/report-store/lung-transplant-rejection-market
DelveInsight's "Lung Transplant Rejection Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Lung Transplant Rejection, historical and forecasted epidemiology as well as the Lung Transplant Rejection market trends in the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.

CAR T-Cell Therapy for Multiple Myeloma Market
https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-market
DelveInsight's "CAR-T Cell Therapy for Multiple Myeloma Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of multiple myeloma and various CAR-Ts used in multiple myeloma, and CAR-Ts historical and forecasted market trends in multiple myeloma in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Insulin Resistance Market
https://www.delveinsight.com/report-store/insulin-resistance-market
DelveInsight's "Insulin Resistance Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Insulin Resistance, historical and forecasted epidemiology as well as the Insulin Resistance market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Dyskinesia Market
https://www.delveinsight.com/report-store/dyskinesia-market
DelveInsight's "Dyskinesia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dyskinesia, historical and forecasted epidemiology as well as the Dyskinesia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemophilia Market
https://www.delveinsight.com/report-store/hemophilia-market
DelveInsight's "Hemophilia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemophilia, historical and forecasted epidemiology as well as the Hemophilia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Paroxysmal Nocturnal Hemoglobinuria Market
https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market
DelveInsight's 'Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of Paroxysmal Nocturnal Hemoglobinuria historical and forecasted epidemiology as well as the Paroxysmal Nocturnal Hemoglobinuria market trends in the United States, the EU4 (Germany, France, Italy, Spain), the UK and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.